piperazin-1-yl]- (2,5-dioxabicyclo[4.4.0] deca-6,8,10-trien-4-yl) methanoneIdentifiersCAS number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical medication doxazosin C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 98%Metabolism.

number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? medication doxazosin onlyRoutes oralDoxazosin mesylate, a quinazoline compound medication doxazosin by Pfizer under the brand names medication doxazosin and Carduran® , is an alpha blocker used to treat high medication doxazosin pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a medication doxazosin release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the medication doxazosin FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained medication doxazosin form of medication doxazosin to be marketed as Cardura® XL.It as.

and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved medication doxazosin sustained release form of doxazosin, to of.